217 related articles for article (PubMed ID: 32598594)
1. [Non - alcoholic fatty liver disease and enteral insufficiency: comorbidity of their development].
Vakhrushev YM; Suchkova EV; Lukashevich AP
Ter Arkh; 2019 Dec; 91(12):84-89. PubMed ID: 32598594
[TBL] [Abstract][Full Text] [Related]
2. [Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases].
Halmos T; Suba I
Orv Hetil; 2017 Dec; 158(52):2051-2061. PubMed ID: 29285942
[TBL] [Abstract][Full Text] [Related]
3. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease.
Akhmedov VA; Gaus OV
Ter Arkh; 2019 Mar; 91(2):143-148. PubMed ID: 31094185
[TBL] [Abstract][Full Text] [Related]
4. Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth.
Rafiei R; Bemanian M; Rafiei F; Bahrami M; Fooladi L; Ebrahimi G; Hemmat A; Torabi Z
Rom J Intern Med; 2018 Jun; 56(2):85-89. PubMed ID: 29101772
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota and non-alcoholic fatty liver disease.
Gkolfakis P; Dimitriadis G; Triantafyllou K
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
[TBL] [Abstract][Full Text] [Related]
6. The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents.
Belei O; Olariu L; Dobrescu A; Marcovici T; Marginean O
J Pediatr Endocrinol Metab; 2017 Oct; 30(11):1161-1168. PubMed ID: 28988228
[TBL] [Abstract][Full Text] [Related]
7. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
Utzeri E; Usai P
World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
[TBL] [Abstract][Full Text] [Related]
8. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
[TBL] [Abstract][Full Text] [Related]
10. Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis.
Tilg H; Mathurin P
Gut; 2016 May; 65(5):728-9. PubMed ID: 26786686
[No Abstract] [Full Text] [Related]
11. [Study on the correlation between small intestinal dendritic cells and non-alcoholic fatty liver disease in mice].
Fang JH; Yu W; Zhou G; Shi JP; Yang WJ; Shen XY; Li GX
Zhonghua Gan Zang Bing Za Zhi; 2019 Sep; 27(9):698-703. PubMed ID: 31594095
[No Abstract] [Full Text] [Related]
12. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience.
Fitriakusumah Y; Lesmana CRA; Bastian WP; Jasirwan COM; Hasan I; Simadibrata M; Kurniawan J; Sulaiman AS; Gani RA
BMC Gastroenterol; 2019 Mar; 19(1):43. PubMed ID: 30894137
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction.
Federico A; Dallio M; Masarone M; Persico M; Loguercio C
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4731-4741. PubMed ID: 27906428
[TBL] [Abstract][Full Text] [Related]
14. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
; Lonardo A; Bellentani S; Argo CK; Ballestri S; Byrne CD; Caldwell SH; Cortez-Pinto H; Grieco A; Machado MV; Miele L; Targher G
Dig Liver Dis; 2015 Dec; 47(12):997-1006. PubMed ID: 26454786
[TBL] [Abstract][Full Text] [Related]
16. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
Ghoshal UC; Goel A; Quigley EMM
Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
[TBL] [Abstract][Full Text] [Related]
18. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.
Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
Nutrients; 2014 Dec; 6(12):5583-99. PubMed ID: 25479248
[TBL] [Abstract][Full Text] [Related]
19. Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.
Sánchez-Jiménez BA; Brizuela-Alcántara D; Ramos-Ostos MH; Alva-López LF; Uribe-Esquivel M; Chávez-Tapia NC
Alcohol; 2018 Jun; 69():63-67. PubMed ID: 29660603
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
Athyros VG; Katsiki N; Doumas M
Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
